Substituted Morpholine Synthesis for High-Purity S-Enantiomers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing syntheses of 2-((2-ethoxyphenoxy)methyl)morpholine analogs, prodrugs, and derivatives suffer from low reaction yield, reaction byproducts, difficult separation of enantiomers, and impurities, particularly those with genotoxicity or toxicity, which hinder the development of safe pharmaceutical products.
Innovation Solution
A novel synthesis method involving the reaction of a compound with (S)-(+)-epichlorohydrin to form intermediates, followed by base and phase transfer catalyst interactions, culminating in the formation of highly pure (S)-enantiomer morpholine derivatives through sulfonylation and recrystallization, with optional conversion to prodrugs via chlorocarbamate intermediates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional synthesis methods are used to produce 2-((2-ethoxyphenoxy)methyl)morpholine analogs, then the basic pharmacologic properties are achieved, but the reaction yield is low and impurities including genotoxic substances are generated
Solution Approach 1:
The synthesis is divided into distinct stages: (a) formation of chlorohydrin intermediate, (b) cyclization to morpholine ring, (c) sulfonylation to form protected intermediates, and (d) deprotection to yield final product. Each stage is optimized independently to maximize yield and minimize impurity formation at each step.
Solution Approach 2:
The patent employs carefully designed intermediate compounds (chlorohydrin, morpholine ring, sulfonyl-protected intermediates) that facilitate smooth progression through the synthesis while preventing side reactions. These intermediates act as mediators that guide the reaction pathway toward the desired product with high selectivity.
2Productivity
If conventional synthesis methods are used, then the synthesis process is completed, but the separation of enantiomers becomes difficult and time-consuming
Solution Approach 1:
The synthesis employs chiral auxiliaries and stereoselective reagents in early stages to establish the desired (S)-enantiomer configuration before final product formation. This preliminary establishment of chirality eliminates the need for time-consuming separation processes later in the synthesis.
Solution Approach 2:
The patent utilizes specific reaction conditions (temperature, solvent, catalysts, pH) that favor the formation of the (S)-enantiomer. By carefully controlling these parameters throughout the synthesis, high enantiomeric excess is achieved directly, avoiding separation requirements.
3Manufacturing precision
If the synthesis aims to produce high purity (S)-enantiomer, then the pharmacological activity is maximized, but the process complexity increases
Solution Approach 1:
The patent applies specific reagents, catalysts, and conditions at particular stages of the synthesis where they are most needed. For example, chiral catalysts are used only in steps requiring stereoselectivity, while standard reagents are used in other steps. This localized application of specialized methods maintains simplicity where possible while achieving high purity where required.
4Reliability
If conventional synthesis routes are used, then the basic product is obtained, but the presence of toxic impurities hinders pharmaceutical development
Solution Approach 1:
The patent employs sulfonyl protecting groups that temporarily mask reactive sites during synthesis, preventing the formation of genotoxic byproducts. These protecting groups are then cleanly removed in a final deprotection step, converting a potential source of impurity into a tool for ensuring product safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high purity and yield of the (S)-enantiomer, reducing impurities and genotoxicity, thereby producing chemically stable compounds suitable for pharmaceutical use.
Implementation Method 1
contacting the chlorohydrin compound with a base and phase transfer catalyst to form an epoxide compound
Implementation Method 2
contacting the diol compound with a base followed by addition of a sulfonyl halide to form an intermediate sulfonate
Implementation Method 3
an intermediate sulfonate that cyclizes in situ to give an N-benzyl protected morpholine compound
Implementation Method 4
forming the HCl salt of the compound of formula IIb and recrystallizing it to afford the highly pure (S)-enantiomer as an HCl salt
Data Source
AI summary
Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof. Further provided are methods of making derivatives and prodrugs of substituted morpholines having the following chemical structure: